| Ms Alisha K Ersland, OTR/L | |
|
516 Sw 38th Terrace, Moore, OK 73160 | |
| (405) 378-2529 | |
| Not Available |
| Full Name | Ms Alisha K Ersland |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapist - Pediatrics |
| Location | 516 Sw 38th Terrace, Moore, Oklahoma |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104911536 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225XP0200X | Occupational Therapist - Pediatrics | 1093 (Oklahoma) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ms Alisha K Ersland, OTR/L 516 Sw 38th Terrace, Moore, OK 73160 Ph: (405) 378-2529 | Ms Alisha K Ersland, OTR/L 516 Sw 38th Terrace, Moore, OK 73160 Ph: (405) 378-2529 |
News Archive
On Monday, September 27, researchers from Albert Einstein College of Medicine of Yeshiva University will hold a congressional briefing in Washington, D.C., aimed at focusing attention on the alarming global diabetes epidemic.
Hospitals whose infection prevention and control programs are led by a director who is board certified in infection prevention and control have significantly lower rates of methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections (BSI) than those that are not led by a certified professional, according to a new study published in the March issue of the American Journal of Infection Control, the official publication of APIC - the Association for Professionals in Infection Control and Epidemiology.
GlaxoSmithKline and Genmab A/S Following the 1st July announcement by GSK and Genmab of an amendment to the collaborative agreement for ofatumumab in which GSK assumed development responsibility for autoimmune indications, GSK and Genmab announced today plans to refocus the development program of ofatumumab in autoimmune indications.
RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutic discovery and development, and Apthera, Inc., a private biotechnology company developing a pipeline of peptide-based immunotherapies for the adjuvant treatment of HER2-positive breast and other cancers, announced today the signing of a definitive merger agreement under which RXi will acquire Apthera.
By melding magnetic and luminescent properties with an easily modified surface, a team of investigators at the National Research Council of Canada have created what could prove to be a highly versatile nanoparticle system for imaging and delivering drugs to tumors.
› Verified 3 days ago
Ms. Linda W Cooper, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 2111 Riverwalk Dr, Moore, OK 73160 Phone: 405-793-7885 Fax: 405-793-7893 | |
Purvi Patel, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 9201 S I 35 Service Rd, Moore, OK 73160 Phone: 405-601-4303 | |
Courtney Noelle Vancil, OT Occupational Therapist Medicare: Medicare Enrolled Practice Location: 1401 Sw 34th St # 300, Moore, OK 73160 Phone: 405-793-7885 | |
Ms. Marie Nicole Arebalo, MOTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1401 Sw 34th St Ste 100, Moore, OK 73160 Phone: 405-793-7885 | |
Jessica Renee Williford, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 9201 S I 35 Service Rd, Moore, OK 73160 Phone: 405-601-4303 | |
Triangle Therapy Connection Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 416 Sw 32nd St, Moore, OK 73160 Phone: 405-474-5626 |